Drug Profile
Atorvastatin/fenofibrate
Alternative Names: AtorFen; LCP-AtorFenLatest Information Update: 02 Oct 2021
Price :
$50
*
At a glance
- Originator LifeCycle Pharma
- Developer Athena Drug Delivery Solutions; LifeCycle Pharma; Veloxis Pharmaceuticals
- Class Antihyperlipidaemics; Butyric acids; Fluorobenzenes; Heptanoic acids; Propionates; Pyrroles; Small molecules
- Mechanism of Action HMG-CoA reductase inhibitors; Peroxisome proliferator-activated receptor alpha agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes - Hyperlipidaemia
Highest Development Phases
- No development reported Dyslipidaemias
Most Recent Events
- 03 Mar 2020 Veloxis Pharmaceuticals has been acquired by Asahi Kasei
- 29 Dec 2011 Atorvastatin/fenofibrate is available for sublicensing as of 29 Dec 2011. http://www.athenadiagnostics.com/content/about/
- 23 Dec 2011 Clinical trials in Dyslipidaemia in emerging markets (PO)